Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)

Objective: To determine the extent of substandard and falsified medicines in the UK. Design: A retrospective review of drug alerts and company-led recalls. Setting: The Medicines and Healthcare Products Regulatory Agency (MHRA) website search for drug alerts issued between 2001 and 2011. Elig...

Full description

Bibliographic Details
Main Authors: Almuzaini, Tariq, Sammons, Helen, Choonara, Imti
Format: Article
Published: BMJ Publishing Group 2013
Online Access:https://eprints.nottingham.ac.uk/2844/
_version_ 1848790890462576640
author Almuzaini, Tariq
Sammons, Helen
Choonara, Imti
author_facet Almuzaini, Tariq
Sammons, Helen
Choonara, Imti
author_sort Almuzaini, Tariq
building Nottingham Research Data Repository
collection Online Access
description Objective: To determine the extent of substandard and falsified medicines in the UK. Design: A retrospective review of drug alerts and company-led recalls. Setting: The Medicines and Healthcare Products Regulatory Agency (MHRA) website search for drug alerts issued between 2001 and 2011. Eligibility criteria: Drug alerts related to quality defect in medicinal products. Main outcome measure: Relevant data about defective medicines reported in drug alerts and company-led recalls, including description of the defect, type of formulation, year of the alert and category of the alert. Results: There were 280 substandard medicines of which 222 were recalled. The two most frequent problems were contamination (74 incidents) and issues related to packaging (98 incidents). Formulations for parenteral administration (117 incidents) were the formulation most frequently affected. There were 11 falsified medicines, as defined by the MHRA, reported over the 11-year period. The number of defective medicines reported by the MHRA increased 10-fold from 5 in 2001 to 50 in 2011. Conclusions: Substandard medicines are a significant problem in the UK. It is uncertain whether the increasing number of reports relates to improved detection or an increase in the number of substandard medicines
first_indexed 2025-11-14T18:19:48Z
format Article
id nottingham-2844
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T18:19:48Z
publishDate 2013
publisher BMJ Publishing Group
recordtype eprints
repository_type Digital Repository
spelling nottingham-28442020-05-04T16:37:47Z https://eprints.nottingham.ac.uk/2844/ Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011) Almuzaini, Tariq Sammons, Helen Choonara, Imti Objective: To determine the extent of substandard and falsified medicines in the UK. Design: A retrospective review of drug alerts and company-led recalls. Setting: The Medicines and Healthcare Products Regulatory Agency (MHRA) website search for drug alerts issued between 2001 and 2011. Eligibility criteria: Drug alerts related to quality defect in medicinal products. Main outcome measure: Relevant data about defective medicines reported in drug alerts and company-led recalls, including description of the defect, type of formulation, year of the alert and category of the alert. Results: There were 280 substandard medicines of which 222 were recalled. The two most frequent problems were contamination (74 incidents) and issues related to packaging (98 incidents). Formulations for parenteral administration (117 incidents) were the formulation most frequently affected. There were 11 falsified medicines, as defined by the MHRA, reported over the 11-year period. The number of defective medicines reported by the MHRA increased 10-fold from 5 in 2001 to 50 in 2011. Conclusions: Substandard medicines are a significant problem in the UK. It is uncertain whether the increasing number of reports relates to improved detection or an increase in the number of substandard medicines BMJ Publishing Group 2013-07-24 Article PeerReviewed Almuzaini, Tariq, Sammons, Helen and Choonara, Imti (2013) Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011). BMJ Open, 3 (7). 10/1-10/10. ISSN 2044-6055 http://bmjopen.bmj.com/content/3/7/e002924.full?rss=1 doi:10.1136/bmjopen-2013-002924 doi:10.1136/bmjopen-2013-002924
spellingShingle Almuzaini, Tariq
Sammons, Helen
Choonara, Imti
Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)
title Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)
title_full Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)
title_fullStr Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)
title_full_unstemmed Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)
title_short Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)
title_sort substandard and falsified medicines in the uk: a retrospective review of drug alerts (2001-2011)
url https://eprints.nottingham.ac.uk/2844/
https://eprints.nottingham.ac.uk/2844/
https://eprints.nottingham.ac.uk/2844/